There were 115,757 NH residents with dementia who self-reported pain in the last 30 days of life. 5 key findings →
Participants: 20,585 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Research
28,580 Alzheimer's and dementia studies in plain English, each scored out of 100.
Functional and cognitive impairments were markedly higher for those who died aged 90 and older- predominantly women-than for those who died aged 85 to 89. 5 key findings →
Participants: 321 Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
In total, 147 participants across 21 US sites were invited to participate and 111 provided informed consent. 5 key findings →
Design: cohort study Participants: 147 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
PLWD proactively enrolled in a dementia care program have high baseline rates of behavioral issues and their caregivers have elevated depression and stress scores. 2 key findings →
Design: longitudinal study Participants: 195 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
In a sample of 1218 new HCBS users (75% female, 77% Black; mean [SD] age, 70.5 [7.5] years), Medicaid HCBS initiation was associated with a decrease in probability of ED use (-2.70 percentage points; 95% CI, -4.18 to -1.22 percentage points) and a decrease in probability of inpatient discharge (-2.63 percentage points; 95% CI, -3.75 to -1.51 percentage points). 5 key findings →
Design: cohort study Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
An increasing number of older adults reside in assisted living (AL) toward the end of life, and it remains unclear if this trend represents an additional place of care and end-of-life transition before eventual nursing home admission. 1 key finding →
Design: cohort study Participants: 273,722 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Oral health is strongly associated with overall health. 5 key findings →
Design: cross-sectional Participants: 1,488 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
We examined state variations in assisted living (AL) regulatory policies for admission/retention, staffing/training, medication management, and dementia care. 3 key findings →
Participants: 46 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Alzheimer's blood-based biomarker (BBM) tests using single biomarkers or ratios are well characterized, but head-to-head comparisons of multi-analyte algorithmic tests on shared cohorts are lacking. 4 key findings →
Design: cross-sectional Participants: 192 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Loneliness, distinct from social isolation, is a subjective sense of social disconnection exacerbating a public health crisis among older adults. 5 key findings →
Design: meta-analysis Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Latino family caregivers of people with dementia face significant challenges and limited access to support. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
The advancement of disease-modifying treatments (DMTs) for Alzheimer's disease (AD), along with the approval of three amyloid-targeting therapies in the US and several other countries, represents a significant development in the treatment landscape, offering new hope for addressing this once untreatable chronic progressive disease. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Recent positive results of three phase III anti-amyloid monoclonal antibody trials are transforming the landscape of disease-modifying therapeutics for Alzheimer's disease, following several decades of failures. 2 key findings →
Design: longitudinal study Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Diagnostic pathways for patients presenting with cognitive complaints may vary across geographies. 1 key finding →
Design: cross-sectional Participants: 6,744 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
To determine the risk for dementia in neurofibromatosis type 1 (NF1) using a Finnish nationwide cohort of individuals with NF1, and data from national registries. 2 key findings →
Participants: 1,349 Evidence: moderate
Full summary, score breakdown and related studies → Original source
This Viewpoint discusses the potential benefits and harms of prior authorization in Medicare Advantage and the health policy implications and opportunities for improvement. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Pneumonia, febrile episodes, and eating problems are frequent complications in patients with advanced dementia, and these complications are associated with high 6-month mortality rates. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Specialised care services were highly prevalent. 5 key findings →
Design: cross-sectional Evidence: low
Full summary, score breakdown and related studies → Original source
Among 4505 respondents aged ≥70 years, 1750 (38.8%) had possible or probable dementia and 2755 (61.2%) had no dementia. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
As full citizens, people with dementia are entitled to engage in social and occupational activities in residential care settings. 1 key finding →
Participants: 73 Evidence: low
Full summary, score breakdown and related studies → Original source
Four themes emerged that relate to stigma in RC-AL: (a) ageism in long-term care; (b) stigma as related to disease and illness; (c) sociocultural aspects of stigma; and (d) RC-AL as a stigmatizing setting. 4 key findings →
Participants: 309 Evidence: low
Full summary, score breakdown and related studies → Original source
The odds of the occurrence and of a greater severity of dementia were higher in 2010/2011 than in 2004/2005. 3 key findings →
Design: cross-sectional Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Approximately half of Medicare beneficiaries are enrolled in Medicare Advantage (MA), a private plan alternative to traditional Medicare (TM). 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The study included 2,284,175 FFS Medicare beneficiaries with an ADRD diagnosis in 2017. 5 key findings →
Participants: 2,284,175 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Discussions revealed that people were generally supportive of this type of research, provided they gave informed consent and that devices were discreet, comfortable and easy to use. 4 key findings →
Participants: 30 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Where “Free full text” comes from
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
How the 0–100 score works — and why some entries are capped
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
- Journal tier up to 10 pts
- Journal's citation record up to 4 pts
- Study design up to 12 pts
- Strength of evidence up to 5 pts
- Peer-review validation up to 10 pts
- How recent up to 5 pts
- Sample size up to 4 pts
- Effect reported up to 3 pts
- Studied in people up to 3 pts
- Randomised / blinded up to 2 pts
- Times cited up to 7 pts
- Citations per year up to 5 pts
- Impact for its field and year up to 6 pts
- Cited by studies here up to 6 pts
- Still being cited up to 4 pts
- Senior author's track record up to 4 pts
- Institution's track record up to 3 pts
- Multi-centre collaboration up to 3 pts
- Indexed in PubMed up to 2 pts
- Free to read up to 2 pts
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 28,580 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
What this library is — and isn't
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 28,580 records, built mostly from automated pulls of Europe PMC (62.2% of the library) and OpenAlex (17.8%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,034 records (3.6% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →